189 related articles for article (PubMed ID: 25315028)
1. 1,25-Dihydroxyvitamin D3 prevents bone loss of the secondary spongiosa in arthritic rats by an increase of bone formation and mineralization and inhibition of bone resorption.
Oelzner P; Petrow PK; Wolf G; Bräuer R
BMC Musculoskelet Disord; 2014 Oct; 15():345. PubMed ID: 25315028
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis.
Neumann T; Oelzner P; Petrow PK; Thoss K; Hein G; Stein G; Bräuer R
Inflamm Res; 2006 Jan; 55(1):32-9. PubMed ID: 16429254
[TBL] [Abstract][Full Text] [Related]
3. High-dose clodronate therapy prevents joint destruction in chronic antigen-induced arthritis of the rat but inhibits bone formation at the axial skeleton.
Oelzner P; Kunze A; Henzgen S; Thoss K; Hein G; Stein G; Bräuer R
Inflamm Res; 2000 Aug; 49(8):424-33. PubMed ID: 11028760
[TBL] [Abstract][Full Text] [Related]
4. Periarticular bone alterations in chronic antigen-induced arthritis: free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa.
Oelzner P; Bräuer R; Henzgen S; Thoss K; Wünsche B; Hersmann G; Abendroth K; Kinne RW
Clin Immunol; 1999 Jan; 90(1):79-88. PubMed ID: 9884355
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats.
Erben RG; Weiser H; Sinowatz F; Rambeck WA; Zucker H
Calcif Tissue Int; 1992 Mar; 50(3):228-36. PubMed ID: 1617497
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat.
Oelzner P; Fleissner-Richter S; Bräuer R; Hein G; Wolf G; Neumann T
Inflamm Res; 2010 Sep; 59(9):731-41. PubMed ID: 20306217
[TBL] [Abstract][Full Text] [Related]
7. 1,25-Dihydroxyvitamin D3 attenuates disease severity and induces synoviocyte apoptosis in a concentration-dependent manner in rats with adjuvant-induced arthritis by inactivating the NF-κB signaling pathway.
Sun HQ; Yan D; Wang QN; Meng HZ; Zhang YY; Yin LX; Yan XF; Li SF
J Bone Miner Metab; 2019 May; 37(3):430-440. PubMed ID: 30097709
[TBL] [Abstract][Full Text] [Related]
8. Role of vitamin D metabolites in the prevention of the osteopenia induced by ovariectomy in the axial and appendicular skeleton of the rat.
Erben RG; Kohn B; Weiser H; Sinowatz F; Rambeck WA
Z Ernahrungswiss; 1990 Dec; 29(4):229-48. PubMed ID: 2080635
[TBL] [Abstract][Full Text] [Related]
9. Chronic administration of 1,25-dihydroxyvitamin D3: increased bone but impaired mineralization.
Wronski TJ; Halloran BP; Bikle DD; Globus RK; Morey-Holton ER
Endocrinology; 1986 Dec; 119(6):2580-5. PubMed ID: 3780540
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D metabolites and bone mineralization in man.
Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
[TBL] [Abstract][Full Text] [Related]
11. Effects of two new vitamin D3 derivatives, 22-oxa-1 alpha-25-dihydroxyvitamin D3 (OCT) and 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3 (ED-71), on bone metabolism in organ culture.
Sato K; Nishii Y; Woodiel FN; Raisz LG
Bone; 1993; 14(1):47-51. PubMed ID: 8443002
[TBL] [Abstract][Full Text] [Related]
12. 1alpha-hydroxyvitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats.
Erben RG; Bante U; Birner H; Stangassinger M
Calcif Tissue Int; 1997 May; 60(5):449-56. PubMed ID: 9115163
[TBL] [Abstract][Full Text] [Related]
13. 24,25(OH)2D3, bone formation, and bone resorption in vitamin D-deficient, azotemic rats.
Goodman WG; Baylink DJ; Sherrard DJ
Calcif Tissue Int; 1984 Mar; 36(2):206-13. PubMed ID: 6430503
[TBL] [Abstract][Full Text] [Related]
14. Mineralization of three-dimensional osteoblast cultures is enhanced by the interaction of 1α,25-dihydroxyvitamin D3 and BMP2 via two specific vitamin D receptors.
Chen J; Dosier CR; Park JH; De S; Guldberg RE; Boyan BD; Schwartz Z
J Tissue Eng Regen Med; 2016 Jan; 10(1):40-51. PubMed ID: 23784946
[TBL] [Abstract][Full Text] [Related]
15. Continuous infusion of 1,25-dihydroxyvitamin D3 stimulates bone turnover in the normal young mouse.
Marie PJ; Travers R
Calcif Tissue Int; 1983 Jul; 35(4-5):418-25. PubMed ID: 6688545
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Stolina M; Schett G; Dwyer D; Vonderfecht S; Middleton S; Duryea D; Pacheco E; Van G; Bolon B; Feige U; Zack D; Kostenuik P
Arthritis Res Ther; 2009; 11(6):R187. PubMed ID: 20003323
[TBL] [Abstract][Full Text] [Related]
17. 1,25 Dihydroxyvitamin D3 modifies cyclosporine-induced bone loss.
Epstein S; Schlosberg M; Fallon M; Thomas S; Movsowitz C; Ismail F
Calcif Tissue Int; 1990 Sep; 47(3):152-7. PubMed ID: 2224590
[TBL] [Abstract][Full Text] [Related]
18. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
19. Bone protective effect of simvastatin in experimental arthritis.
Funk JL; Chen J; Downey KJ; Clark RA
J Rheumatol; 2008 Jun; 35(6):1083-91. PubMed ID: 18464303
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of 1,25-dihydroxyvitamin D
Li ZF; Cao LH; Wang Y; Zhang Z; Fan MW; Xu QA
Arch Oral Biol; 2016 Dec; 72():146-156. PubMed ID: 27597534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
